Advances in Traditional Chinese Medicine research in diabetic kidney disease treatment

References

• Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH. 2016. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 316(6):602–610. doi:10.1001/jama.2016.10924.
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. 2017. Diabetic kidney disease challenges, progress, and possibilities. Clin J Am Soc Nephrol. 12(12):2032–2045. doi:10.2215/CJN.11491116.
   PubMed Web of Science ®Google Scholar
• Bai YL, Han LL, Qian JH, Wang HZ. 2021. Molecular mechanism of puerarin against diabetes and its complications. Front Pharmacol. 12:780419. doi:10.3389/fphar.2021.780419.
   PubMedGoogle Scholar
• Bao Y, Liang W, Ye Y, Yi B. 2021. PERK-dependent activation of the JAK2/STAT3 pathway contributes to high glucose-induced extracellular matrix deposition in renal tubular epithelial cells. Int J Endocrinol. 2021:8475868–8475869. doi:10.1155/2021/8475868.
   PubMed Web of Science ®Google Scholar
• Barrera-Chimal J, Jaisser F. 2020. Pathophysiologic mechanisms in diabetic kidney disease: a focus on current and future therapeutic targets. Diabetes Obes Metab. 22 Suppl 1(S1):16–31. doi:10.1111/dom.13969.
   PubMedGoogle Scholar
• Bertheloot D, Latz E, Franklin BS. 2021. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol Immunol. 18(5):1106–1121. doi:10.1038/s41423-020-00630-3.
   PubMed Web of Science ®Google Scholar
• Bonner R, Albajrami O, Hudspeth J, Upadhyay A. 2020. Diabetic kidney disease. Prim Care. 47(4):645–659. doi:10.1016/j.pop.2020.08.004.
   PubMed Web of Science ®Google Scholar
• Brezniceanu M-L, Lau CJ, Godin N, Chénier I, Duclos A, Ethier J, Filep JG, Ingelfinger JR, Zhang S-L, Chan JSD. 2010. Reactive oxygen species promote caspase-12 expression and tubular apoptosis in diabetic nephropathy. J Am Soc Nephrol. 21(6):943–954. doi:10.1681/ASN.2009030242.
   PubMed Web of Science ®Google Scholar
• Chan KW, Chow TY, Yu KY, Feng YB, Lao LX, Bian ZX, Wong VT, Tang SCW. 2022. Effectiveness of integrative Chinese western medicine for chronic kidney disease and diabetes: a retrospective cohort study. Am J Chin Med. 50(2):371–388. doi:10.1142/S0192415X2250015X.
   PubMedGoogle Scholar
• Chan KW, Yu KY, Yiu WH, Xue R, Lok SWY, Li HY, Zou YX, Ma JY, Lai KN, Tang SCW. 2022. Potential therapeutic targets of Rehmannia formulations on diabetic nephropathy: a comparative network pharmacology analysis. Front Pharmacol. 13:794139. doi:10.3389/fphar.2022.794139.
   PubMed Web of Science ®Google Scholar
• Chang X, Li L, Wang B, Huang C, Liu X, Liu H, Zhang P. 2020. Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR. J Formos Med Assoc. 119(3):685–692. doi:10.1016/j.jfma.2019.11.001.
   PubMed Web of Science ®Google Scholar
• Chen D, Huang D, Hu TT, Chen F. 2021. Efficacy of restricting dietary protein intake combined with Buyang Huanwu Decoction in treating diabetic nephropathy and its effect on patients’ inflammatory factor levels. Evid Based Complement Alternat Med. 2021:5906244–5906246. doi:10.1155/2021/5906244.
   PubMed Web of Science ®Google Scholar
• Chen Y, He X, Yuan X, Hong J, Bhat O, Li G, Li P-L, Guo J. 2018. NLRP3 inflammasome formation and activation in nonalcoholic steatohepatitis: therapeutic target for antimetabolic syndrome remedy FTZ. Oxid Med Cell Longev. 2018:2901871–2901813. doi:10.1155/2018/2901871.
   PubMed Web of Science ®Google Scholar
• Cheng D, Gao L, Su S, Sargsyan D, Wu R, Raskin I, Kong A-N. 2019. Moringa isothiocyanate activates Nrf2: potential role in diabetic nephropathy. Aaps J. 21(2):31. doi:10.1208/s12248-019-0301-6.
   PubMed Web of Science ®Google Scholar
• Cheng L, Wang M, Zhang Z, Shao F. 2021. Clinical efficacy of Dangguibuxue Decoction as an adjuvant therapy for diabetic nephropathy: a meta-analysis. Chin Gen Prac. 24:3477–3483.
   Google Scholar
• Colombo M, McGurnaghan SJ, Blackbourn LAK, Dalton RN, Dunger D, Bell S, Petrie JR, Green F, MacRury S, McKnight JA, et al. 2020. Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. Diabetologia. 63(4):788–798. doi:10.1007/s00125-019-05081-8.
   PubMed Web of Science ®Google Scholar
• Cui FQ, Gao YB, Wang YF, Meng Y, Cai Z, Shen C, Jiang XC, Zhao WJ. 2021. Effect of Tang-Shen-Ning decoction on podocyte epithelial-esenchymal transformation via inhibiting Wnt/Beta-catenin pathway in diabetic mice. Ann Palliat Med. 10(12):12921–12936. doi:10.21037/apm-20-602.
   PubMed Web of Science ®Google Scholar
• Cui K, Zhang S, Jiang X, Xie W. 2016. Novel synergic antidiabetic effects of Astragalus polysaccharides combined with Crataegus flavonoids via improvement of islet function and liver metabolism. Mol Med Rep. 13(6):4737–4744. doi:10.3892/mmr.2016.5140.
   PubMed Web of Science ®Google Scholar
• Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y. 2009. Wnt/beta-Catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol. 20(9):1997–2008. doi:10.1681/ASN.2009010019.
   PubMed Web of Science ®Google Scholar
• Dai H, Zhao C, Xie Y, Duan L. 2023. Effect of Jinlida granule combined with irbesartan on diabetic nephropathy and its influence on immune function. Chin Arch Tradit Chin Med. 41:202–205.
   Google Scholar
• Darenskaya MA, Kolesnikova LI, Kolesnikov SI. 2021. Oxidative stress: pathogenetic role in diabetes mellitus and its complications and therapeutic approaches to correction. Bull Exp Biol Med. 171(2):179–189. doi:10.1007/s10517-021-05191-7.
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al. 2012. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 149(5):1060–1072. doi:10.1016/j.cell.2012.03.042.
   PubMed Web of Science ®Google Scholar
• Duni A, Liakopoulos V, Roumeliotis S, Peschos D, Dounousi E. 2019. Oxidative stress in the pathogenesis and evolution of chronic kidney disease: untangling Ariadne’s thread. Int J Mol Sci. 20(15):3711. doi:10.3390/ijms20153711.
   PubMed Web of Science ®Google Scholar
• Fang, Zhao J. 2012. Clinical observation on 60 cases of early diabetes nephropathy treated with Cistanchi Guiyishen capsule. Clin J Tradit Chin Med. 24:124–125.
   Google Scholar
• Fang J, Chen Z, Guo Q, Chen C, Wang C, Xie T, Sun R, Liu L, Zhang X. 2016. Regulatory effect of Chinese drugs for stasis removing and collaterals dredging on the expressions of podocin and CD2AP in podocyte slit diaphragm of diabetic nephropathy rats. Chin J Integr Tradit West Med. 36:835–841.
   Google Scholar
• Faselis C, Katsimardou A, Imprialos K, Deligkaris P, Kallistratos M, Dimitriadis K. 2020. Microvascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 18(2):117–124. doi:10.2174/1570161117666190502103733.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu T, Nan Z, Zhen Z, Zhou Q. 2011. TCM diagnosis and treatment standard for diabetes and kidney disease. World J Integr Tradit West Med. 6:548–552.
   Google Scholar
• Gao YW, Su X, Xue TQ, Zhang N. 2023. The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease. Biomed Pharmacother. 163:114598. doi:10.1016/j.biopha.2023.114598.
   PubMed Web of Science ®Google Scholar
• Guo HJ, Cao AL, Chu S, Wang Y, Zang YJ, Mao XD, Wang H, Wang YM, Liu C, Zhang XM, et al. 2016. Astragaloside IV attenuates podocyte apoptosis mediated by endoplasmic reticulum stress through upregulating Sarco/Endoplasmic reticulum Ca2+-ATPase 2 expression in diabetic nephropathy. Front Pharmacol. 7:500. doi:10.3389/fphar.2016.00500.
   PubMed Web of Science ®Google Scholar
• Guo HJ, Wang Y, Zhang XM, Zang YJ, Zhang Y, Wang L, Wang H, Wang YM, Cao AL, Peng W. 2017. Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction AMPK alpha-regulated autophagy induction in streptozotocin-induced diabetic nephropathy. Sci Rep. 7(1):6852. doi:10.1038/s41598-017-07061-7.
   PubMedGoogle Scholar
• Guo S, Wang Y, Guo D, Wang Y, Zhou C, Chen Z. 2021. A multicenter randomized controlled trial of 163 cases of stage III and IV diabetes nephropathy with deficiency of both qi and yin and accumulation of blood stasis in collaterals treated by Yiqi Yangyin Xiaozheng Tongluo recipe combined with western medicine. J Tradit Chin Med. 62:1606–1611.
   Google Scholar
• Hernandez LF, Eguchi N, Whaley D, Alexander M, Tantisattamo E, Ichii H. 2022. Anti-oxidative therapy in diabetic nephropathy. Front Biosci 14(2):14. doi:10.31083/j.fbs1402014.
   Google Scholar
• Higgins C. 2001. Diagnosing diabetes: blood glucose and the role of the laboratory. Br J Nurs. 10(4):230–236. doi:10.12968/bjon.2001.10.4.5372.
   PubMedGoogle Scholar
• Hoo RLC, Wong JYL, Qiao CF, Xu A, Xu HX, Lam KSL. 2010. The effective fraction isolated from Radix Astragali alleviates glucose intolerance, insulin resistance and hypertriglyceridemia in db/db diabetic mice through its anti-inflammatory activity. Nutr Metab. 7:67.
   Google Scholar
• Hu QC, Chen Y, Deng XY, Li YB, Ma X, Zeng JH, Zhao YL. 2023. Diabetic nephropathy: focusing on pathological signals, clinical treatment, and dietary regulation. Biomed Pharmacother. 159:114252. doi:10.1016/j.biopha.2023.114252.
   PubMed Web of Science ®Google Scholar
• Hu QC, Jiang L, Yan Q, Zeng JH, Ma X, Zhao YL. 2023. A natural products solution to diabetic nephropathy therapy. Pharmacol Ther. 241:108314. doi:10.1016/j.pharmthera.2022.108314.
   PubMed Web of Science ®Google Scholar
• Hu X, Wang M, Bei W, Han Z, Guo J. 2014. The Chinese herbal medicine FTZ attenuates insulin resistance via IRS1 and PI3K in vitro and in rats with metabolic syndrome. J Transl Med. 12(1):47. doi:10.1186/1479-5876-12-47.
   PubMedGoogle Scholar
• Hu XB, Duan TT, Wu Z, Tang CF, Cao ZH. 2021. Puerarin inhibits the PERK-eIF2 alpha-ATF4-CHOP pathway through inactivating JAK2/STAT3 signal in pancreatic beta-cells. Am J Chin Med. 49(7):1723–1738. doi:10.1142/S0192415X21500816.
   PubMedGoogle Scholar
• Huang D, Shen P, Wang C, Gao J, Ye C, Wu F. 2022. Calycosin plays a protective role in diabetic kidney disease through the regulation of ferroptosis. Pharm Biol. 60(1):990–996. doi:10.1080/13880209.2022.2067572.
   PubMed Web of Science ®Google Scholar
• Huang F, Wang Q, Guo F, Zhao Y, Ji L, An T, Song Y, Liu Y, He Y, Qin G. 2019. FoxO1-mediated inhibition of STAT1 alleviates tubulointerstitial fibrosis and tubule apoptosis in diabetic kidney disease. EBioMedicine. 48:491–504. doi:10.1016/j.ebiom.2019.09.002.
   PubMed Web of Science ®Google Scholar
• Huang W, Xue H, Gu Z, Liu R, Tian Z, Liu F, Lu M. 2019. Progress and review of Traditional Chinese Medicine research on Pyroptosis. Lishizhen Med Mater Med Res. 30:1961–1963. Chinese
   Google Scholar
• Idowu AA, Ajose AO, Adedeji AT, Adegoke AO, Jimoh KA. 2017. Microalbuminuria, other markers of nephropathy and biochemical derangements in type 2 diabetes mellitus: relationships and determinants. Ghana Med J. 51:56–63.
   PubMedGoogle Scholar
• Ighodaro OM. 2018. Molecular pathways associated with oxidative stress in diabetes mellitus. Biomed Pharmacother. 108:656–662. doi:10.1016/j.biopha.2018.09.058.
   PubMed Web of Science ®Google Scholar
• Jha JC, Banal C, Chow BSM, Cooper ME, Jandeleit-Dahm K. 2016. Diabetes and kidney disease: role of oxidative stress. Antioxid Redox Signal. 25(12):657–684. doi:10.1089/ars.2016.6664.
   PubMed Web of Science ®Google Scholar
• Jiang X, Stockwell BR, Conrad M. 2021. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 22(4):266–282. doi:10.1038/s41580-020-00324-8.
   PubMed Web of Science ®Google Scholar
• Jin D, Huang WJ, Meng X, Yang F, Bao Q, Zhang MZ, Yang YN, Ni Q, Lian FM, Tong XL. 2019. Chinese herbal medicine Tangshen Formula treatment for type 2 diabetic kidney disease in the early stage: study protocol for a randomized controlled trial. Trials. 20(1):756. doi:10.1186/s13063-019-3821-6.
   PubMedGoogle Scholar
• Kanwar YS, Sun L, Xie P, Liu F-y, Chen S. 2011. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol. 6(1):395–423. doi:10.1146/annurev.pathol.4.110807.092150.
   PubMed Web of Science ®Google Scholar
• Kawarada Y, Inoue Y, Kawasaki F, Fukuura K, Sato K, Tanaka T, Itoh Y, Hayashi H. 2016. TGF-beta induces p53/Smads complex formation in the PAI-1 promoter to activate transcription. Sci Rep. 6(1):35483. doi:10.1038/srep35483.
   PubMedGoogle Scholar
• Krolewski AS, Skupien J, Rossing P, Warram JH. 2017. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int. 91(6):1300–1311. doi:10.1016/j.kint.2016.10.046.
   PubMed Web of Science ®Google Scholar
• Lavoz C, Matus YS, Orejudo M, Carpio JD, Droguett A, Egido J, Mezzano S, Ruiz-Ortega M. 2019. Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy. Kidney Int. 95(6):1418–1432. doi:10.1016/j.kint.2018.12.031.
   PubMed Web of Science ®Google Scholar
• Li B-y, Peng H, Xiong D-l, Yi J, Chen H. 2015. Efficacy observation of treating diabetic nephropathy by shenshuaining granule combined telmisartan tablet. Chin J Integr Tradit West Med. 35:142–146.
   Google Scholar
• Li H, Wang P, Huang F, Jin J, Wu H, Zhang B, Wang Z, Shi H, Wu X. 2018. Astragaloside IV protects blood-brain barrier integrity from LPS-induced disruption via activating Nrf2 antioxidant signaling pathway in mice. Toxicol Appl Pharmacol. 340:58–66. doi:10.1016/j.taap.2017.12.019.
   PubMed Web of Science ®Google Scholar
• Li XF, Xu J, Liu LJ, Wang F, He SL, Su Y, Dong CP. 2019. Efficacy of low-protein diet in diabetic nephropathy: a meta-analysis of randomized controlled trials. Lipids Health Dis. 18(1):82. doi:10.1186/s12944-019-1007-6.
   PubMed Web of Science ®Google Scholar
• Lin E, Erickson KF. 2020. Payer mix among patients receiving dialysis. JAMA. 324(9):900–901. doi:10.1001/jama.2020.10771.
   PubMed Web of Science ®Google Scholar
• Lin L, Wang Q, Yi Y, Wang S, Qiu Z. 2016. Liuwei Dihuang pills enhance the effect of western medicine in treating diabetic nephropathy: a meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2016:1509063–1509069. doi:10.1155/2016/1509063.
   PubMedGoogle Scholar
• Liu IM, Tzeng T-F, Liou S-S, Chang CJ. 2012. Beneficial effect of Traditional Chinese medicinal formula Danggui-Shaoyao-San on advanced glycation end-product-mediated renal injury in streptozotocin-diabetic rats. Evid Based Complement Alternat Med. 2012:140103. doi:10.1155/2012/140103.
   PubMed Web of Science ®Google Scholar
• Liu J, Gao L-D, Fu B, Yang H-T, Zhang L, Che S-Q, Xu Y, Du X, Liu Z-C, Xue Y, et al. 2022. Efficacy and safety of Zicuiyin decoction on diabetic kidney disease: a multicenter, randomized controlled trial. Phytomedicine. 100:154079. doi:10.1016/j.phymed.2022.154079.
   PubMed Web of Science ®Google Scholar
• Liu M, He Q, Mo X. 2020. Clinical observation of Tangshenkang capsule on the treatment of early diabetic nephropathy with the deficiency of both qi and yin complicated by stasis. Chin J Tradit Chin Med Pharm. 35:5316–5319.
   Google Scholar
• Liu P, Zhang ZD, Li Y. 2021. Relevance of the pyroptosis-related inflammasome pathway in the pathogenesis of diabetic kidney disease. Front Immunol. 12:603416. doi:10.3389/fimmu.2021.603416.
   PubMed Web of Science ®Google Scholar
• Liu XD, Yao L, Sun D, Zhu XW, Liu Q, Xu TH, Wang LN. 2016. Effect of breviscapine injection on clinical parameters in diabetic nephropathy: a meta-analysis of randomized controlled trials. Exp Ther Med. 12(3):1383–1397. doi:10.3892/etm.2016.3483.
   PubMed Web of Science ®Google Scholar
• Lu B, Bei-Bei H, Qian G, Jing XU, Jing F, Jiang-Hua Z, Zhi-Qiang C. 2017. Expression of Wnt/β-catenin pathway in diabetic nephropathy rats and intervention effect of Chinese materia medica for dispersing blood stasis and dredging collaterals. Chin Tradit Herbal Drugs. 48:946–950.
   Google Scholar
• Lu J, Chen X, Zhang Y, Xu J, Zhang L, Li Z, Liu W, Ouyang J, Han S, He X. 2013. Astragalus polysaccharide induces anti-inflammatory effects dependent on AMPK activity in palmitate-treated RAW264.7 cells. Int J Mol Med. 31(6):1463–1470. doi:10.3892/ijmm.2013.1335.
   PubMed Web of Science ®Google Scholar
• Lu ZZ, Zhong YF, Liu WY, Xiang L, Deng YY. 2019. The efficacy and mechanism of Chinese herbal medicine on diabetic kidney disease. J Diabetes Res. 2019:2697672–2697614. doi:10.1155/2019/2697672.
   PubMed Web of Science ®Google Scholar
• Ma J, Li YJ, Chen X, Kwan T, Chadban SJ, Wu H. 2019. Interleukin 17A promotes diabetic kidney injury. Sci Rep. 9(1):2264. doi:10.1038/s41598-019-38811-4.
   PubMedGoogle Scholar
• Ma L, Wu F, Shao Q, Chen G, Xu L, Lu F. 2021. Baicalin alleviates oxidative stress and inflammation in diabetic nephropathy via Nrf2 and MAPK signaling pathway. Drug Des Devel Ther. 15:3207–3221. doi:10.2147/DDDT.S319260.
   PubMed Web of Science ®Google Scholar
• Marathe PH, Gao HX, Close KL. 2017. American Diabetes Association standards of medical care in diabetes 2017. J Diabetes. 9(4):320–324. doi:10.1111/1753-0407.12524.
   PubMed Web of Science ®Google Scholar
• Matsui I, Ito T, Kurihara H, Imai E, Ogihara T, Hori M. 2007. Snail, a transcriptional regulator, represses nephrin expression in glomerular epithelial cells of nephrotic rats. Lab Invest. 87(3):273–283. doi:10.1038/labinvest.3700518.
   PubMed Web of Science ®Google Scholar
• Mo HY, Ren Q, Song DY, Xu B, Zhou D, Hong X, Hou FF, Zhou LL, Liu YH. 2022. CXCR4 induces podocyte injury and proteinuria by activating beta-catenin signaling. Theranostics. 12(2):767–781. doi:10.7150/thno.65948.
   PubMed Web of Science ®Google Scholar
• Nie XH, Jia OY, Xing Y, Li DY, Liu R, Xu RX. 2016. Calycosin inhibits migration and invasion through modulation of transforming growth factor beta-mediated mesenchymal properties in U87 and U251 cells. Drug Des Devel Ther. 10:767–779. doi:10.2147/DDDT.S90457.
   PubMed Web of Science ®Google Scholar
• Nitin S. 2010. HbA1c and factors other than diabetes mellitus affecting it. Singapore Med J. 51(8):616–622.
   PubMed Web of Science ®Google Scholar
• Pan J, Li H, Shi J. 2022. Clinical application of the classical theory of Traditional Chinese Medicine in diabetic nephropathy. Comput Math Methods Med. 2022:4066385.
   PubMed Web of Science ®Google Scholar
• Pang G-M, Li F-X, Yan Y, Zhang Y, Kong L-L, Zhu P, Wang K-F, Zhang F, Liu B, Lu C. 2019. Herbal medicine in the treatment of patients with type 2 diabetes mellitus. Chin Med J. 132(1):78–85. doi:10.1097/CM9.0000000000000006.
   PubMed Web of Science ®Google Scholar
• Papadopoulou-Marketou N, Paschou SA, Marketos N, Adamidi S, Adamidis S, Kanaka-Gantenbein C. 2018. Diabetic nephropathy in type 1 diabetes. Minerva Med. 109(3):218–228. doi:10.23736/S0026-4806.17.05496-9.
   PubMed Web of Science ®Google Scholar
• Ritz E, Orth SR. 1999. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 341(15):1127–1133. doi:10.1056/NEJM199910073411506.
   PubMed Web of Science ®Google Scholar
• Robertson RP. 2023. Nrf2 and antioxidant response in animal models of type 2 diabetes. Int J Mol Sci. 24(4):3082. doi:10.3390/ijms24043082.
   PubMed Web of Science ®Google Scholar
• Roumeliotis A, Roumeliotis S, Tsetsos F, Georgitsi M, Georgianos PI, Stamou A, Vasilakou A, Kotsa K, Tsekmekidou X, Paschou P, et al. 2021. Oxidative stress genes in diabetes mellitus type 2: association with diabetic kidney disease. Oxid Med Cell Longev. 2021:2531062–2531010. doi:10.1155/2021/2531062.
   PubMed Web of Science ®Google Scholar
• Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, Isaacs SD, Izuora KE, Wang CCL, Twining CL, et al. 2023. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm-2023 update. Endocr Pract. 29(5):305–340. doi:10.1016/j.eprac.2023.02.001.
   PubMed Web of Science ®Google Scholar
• Sattarinezhad A, Roozbeh J, Yeganeh BS, Omrani GR, Shams M. 2019. Resveratrol reduces albuminuria in diabetic nephropathy: a randomized double-blind placebo-controlled clinical trial. Diabetes Metab. 45(1):53–59. doi:10.1016/j.diabet.2018.05.010.
   PubMed Web of Science ®Google Scholar
• Schena FP, Gesualdo L. 2005. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol. 16(3_suppl_1):S30–S33. doi:10.1681/asn.2004110970.
   PubMedGoogle Scholar
• Schnell O, Crocker JB, Weng J. 2017. Impact of HbA1c testing at point of care on diabetes management. J Diabetes Sci Technol. 11(3):611–617. doi:10.1177/1932296816678263.
   PubMedGoogle Scholar
• Schunk SJ, Floege J, Fliser D, Speer T. 2021. WNT-beta-catenin signalling – a versatile player in kidney injury and repair. Nat Rev Nephrol. 17(3):172–184. doi:10.1038/s41581-020-00343-w.
   PubMed Web of Science ®Google Scholar
• Selby NM, Taal MW. 2020. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 22(S1):3–15. doi:10.1111/dom.14007.
   PubMedGoogle Scholar
• Shahzad K, Fatima S, Khawaja H, Elwakiel A, Gadi I, Ambreen S, Zimmermann S, Mertens PR, Biemann R, Isermann B. 2022. Podocyte-specific NLRP3 inflammasome activation promotes diabetic kidney disease. Kidney Int. 102(4):766–779. doi:10.1016/j.kint.2022.06.010.
   PubMed Web of Science ®Google Scholar
• Shen S, Ji C, Wei K. 2022. Cellular senescence and regulated cell death of tubular epithelial cells in diabetic kidney disease. Front Endocrinol. 13:924299. doi:10.3389/fendo.2022.924299.
   PubMed Web of Science ®Google Scholar
• Sousa BC, Pitt AR, Spickett CM. 2017. Chemistry and analysis of HNE and other prominent carbonyl-containing lipid oxidation compounds. Free Radic Biol Med. 111:294–308. doi:10.1016/j.freeradbiomed.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Stephens JW, Brown KE, Min TZ. 2020. Chronic kidney disease in type 2 diabetes: implications for managing glycaemic control, cardiovascular and renal risk. Diabetes Obes Metab. 22(S1):32–45. doi:10.1111/dom.13942.
   PubMedGoogle Scholar
• Sulaiman MK. 2019. Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. Diabetol Metab Syndr. 11(1):7. doi:10.1186/s13098-019-0403-4.
   PubMedGoogle Scholar
• Sun C, Xie Q, Meng Q. 2015. Distribution of TCM syndrome elements in patients with diabetic nephropathy: a literature review. J Beijing Univ Tradit Chin Med. 38:266–270.
   Google Scholar
• Sun G-d, Li C-y, Cui W-p, Guo Q-y, Dong C-q, Zou H-b, Liu S-j, Dong W-p, Miao L-n 2016. Review of herbal Traditional Chinese Medicine for the treatment of diabetic nephropathy. J Diabetes Res. 2016:5749857–5749818. doi:10.1155/2016/5749857.
   PubMed Web of Science ®Google Scholar
• Tanase DM, Gosav EM, Anton MI, Floria M, Isac PNS, Hurjui LL, Tarniceriu CC, Costea CF, Ciocoiu M, Rezus C. 2022. Oxidative stress and NRF2/KEAP1/ARE pathway in diabetic kidney disease (DKD): new perspectives. Biomolecules. 12(9):1227. doi:10.3390/biom12091227.
   PubMed Web of Science ®Google Scholar
• Tang G, Li S, Zhang C, Chen H, Wang N, Feng Y. 2021. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management. Acta Pharm Sin B. 11(9):2749–2767. doi:10.1016/j.apsb.2020.12.020.
   PubMed Web of Science ®Google Scholar
• Tang X, Shen H, Chen J, Wang X, Zhang Y, Chen L-l, Rukachaisirikul V, Jiang H-l, Shen X. 2011. Activating transcription factor 6 protects insulin receptor from ER stress-stimulated desensitization via p42/44 ERK pathway. Acta Pharmacol Sin. 32(9):1138–1147. doi:10.1038/aps.2011.75.
   PubMed Web of Science ®Google Scholar
• Toth-Manikowski S, Atta MG. 2015. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res. 2015:697010–697016. doi:10.1155/2015/697010.
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, Uribarri J. 2022. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 102(2):248–260. doi:10.1016/j.kint.2022.05.012.
   PubMed Web of Science ®Google Scholar
• Uruno A, Yagishita Y, Yamamoto M. 2015. The Keap1-Nrf2 system and diabetes mellitus. Arch Biochem Biophys. 566:76–84. doi:10.1016/j.abb.2014.12.012.
   PubMed Web of Science ®Google Scholar
• Volpe CMO, Villar-Delfino PH, dos Anjos PMF, Nogueira-Machado JA. 2018. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 9(2):119. doi:10.1038/s41419-017-0135-z.
   PubMed Web of Science ®Google Scholar
• Voroneanu L, Siriopol D, Dumea R, Badarau S, Kanbay M, Afsar B, Gavrilovici C, Covic A. 2017. Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial. Int Urol Nephrol. 49(12):2195–2204. doi:10.1007/s11255-017-1697-5.
   PubMed Web of Science ®Google Scholar
• Wang B, Chen S, Yan X, Li M, Li D, Ti G. 2015. The therapeutic effect and possible harm of Puerarin for treatment of stage III diabetic nephropathy: a meta-analysis. Altern Ther Health Med. 21:36–44.
   PubMed Web of Science ®Google Scholar
• Wang B, Ni Q, Wang X, Lin L. 2012. Meta-analysis of the clinical effect of ligustrazine on diabetic nephropathy. Am J Chin Med. 40(1):25–37. doi:10.1142/S0192415X12500036.
   PubMed Web of Science ®Google Scholar
• Wang EY, Wang L, Ding R, Zhai MT, Ge RR, Zhou P, Wang TT, Fang HY, Wang JH, Huang JL. 2020. Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy. Pharmacol Res. 157:104831. doi:10.1016/j.phrs.2020.104831.
   PubMed Web of Science ®Google Scholar
• Wang HY, Zhang R, Wu XJ, Chen YF, Ji W, Wang JS, Zhang YW, Xia Y, Tang YQ, Yuan JX. 2021. The Wnt signaling pathway in diabetic nephropathy. Front Cell Dev Biol. 9:701547. doi:10.3389/fcell.2021.701547.
   PubMed Web of Science ®Google Scholar
• Wang M-R, Yu L-H, Wang T-T, Wang Y-M, Han M-X. 2018. Effect of Shenqi Dihuang decoction on inflammatory factor, renal function and microcirculation in patients with early diabetic nephropathy. Chin J Chin Mater Med. 43:1276–1281.
   Google Scholar
• Wang X, Xu Y, Chu C, Li H, Mi J, Wen Z, Zhang S, Wang Q, Quan S. 2019. Effect of safflower yellow on early type II diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials. J Pediatr Endocrinol Metab. 32(7):653–665. doi:10.1515/jpem-2018-0425.
   PubMed Web of Science ®Google Scholar
• Wang X-Q, Wang L, Tu Y-C, Zhang YC. 2018. Traditional Chinese Medicine for refractory nephrotic syndrome: strategies and promising treatments. Evid Based Complement Alternat Med. 2018:8746349. doi:10.1155/2018/8746349.
   PubMed Web of Science ®Google Scholar
• Wang Y, Bi R, Quan F, Cao Q, Lin Y, Yue C, Cui X, Yang H, Gao X, Zhang D. 2020. Ferroptosis involves in renal tubular cell death in diabetic nephropathy. Eur J Pharmacol. 888:173574. doi:10.1016/j.ejphar.2020.173574.
   PubMed Web of Science ®Google Scholar
• Wang ZS, Xiong F, Xie XH, Chen D, Pan JH, Cheng L. 2015. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress. BMC Nephrol. 16(1):44. doi:10.1186/s12882-015-0031-7.
   PubMedGoogle Scholar
• Warren AM, Knudsen ST, Cooper ME. 2019. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies. Expert Opin Ther Targets. 23(7):579–591. doi:10.1080/14728222.2019.1624721.
   PubMed Web of Science ®Google Scholar
• Watanabe J, Takiyama Y, Honjyo J, Makino Y, Fujita Y, Tateno M, Haneda M. 2016. Role of IGFBP7 in diabetic nephropathy: TGF-beta 1 induces IGFBP7 via Smad2/4 in human renal proximal tubular epithelial cells. PLoS One. 11(3):e0150897. doi:10.1371/journal.pone.0150897.
   PubMed Web of Science ®Google Scholar
• Wen YM, Yan MH, Zhang BX, Li P. 2017. Chinese medicine for diabetic kidney disease in China. Nephrology. 22(S4):50–55. doi:10.1111/nep.13149.
   PubMedGoogle Scholar
• Xiang L, Jiang P, Zhou L, Sun X, Bi J, Cui L, Nie X, Luo R, Zhao X, Liu Y. 2016. Additive effect of Qidan Dihuang grain, a traditional Chinese medicine, and angiotensin receptor blockers on albuminuria levels in patients with diabetic nephropathy: a randomized, parallel-controlled trial. Evid Based Complement Alternat Med. 2016:1064924–1064928. doi:10.1155/2016/1064924.
   PubMed Web of Science ®Google Scholar
• Xie H, Shi Y, Zhou Y, Liu H. 2022. TMBIM6 promotes diabetic tubular epithelial cell survival and albumin endocytosis by inhibiting the endoplasmic reticulum stress sensor, IRE1 alpha. Mol Biol Rep. 49(10):9181–9194. doi:10.1007/s11033-022-07744-z.
   PubMed Web of Science ®Google Scholar
• Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. 2018. Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. Kidney Int. 93(3):741–752. doi:10.1016/j.kint.2017.08.033.
   PubMed Web of Science ®Google Scholar
• Xu XH, Chen B, Huang QC, Wu YN, Liang T. 2020. The effects of puerarin on autophagy through regulating of the PERK/eIF2 alpha/ATF4 signaling pathway influences renal function in diabetic nephropathy. Diabetes Metab Syndr Obes. 13:2583–2592. doi:10.2147/DMSO.S256457.
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang BX, Lu XG, Yan MH, Wen YM, Zhao TT, Li P. 2016. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease. BMC Complement Altern Med. 16(1):246. doi:10.1186/s12906-016-1228-4.
   PubMedGoogle Scholar
• Yang XP, Lu FE, Li LL, Li JB, Luo JL, Zhang SY, Liu XQ, Chen G. 2019. Wu-Mei-wan protects pancreatic cells by inhibiting NLRP3 inflammasome activation in diabetic mice. BMC Complement Altern Med. 19(1):35. doi:10.1186/s12906-019-2443-6.
   PubMedGoogle Scholar
• Yang Y-Q, Tan H-B, Zhang X-Y, Zhang Y-Z, Lin Q-Y, Huang M-Y, Lin Z-Y, Mo J-Z, Zhang Y, Lan T, et al. 2022. The Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against renal injury and inflammation in mice with diabetic kidney disease. J Ethnopharmacol. 292:115165. doi:10.1016/j.jep.2022.115165.
   PubMed Web of Science ®Google Scholar
• Yang YY, Deng RR, Chen Z, Yao LY, Yang XD, Xiang DX. 2021. Piperazine ferulate attenuates high glucose-induced mesangial cell injury via the regulation of p66(Shc). Mol Med Rep. 23(5):12. doi:10.3892/mmr.2021.12013.
   PubMed Web of Science ®Google Scholar
• Ye W-c, Ye J-z, Zheng C, He X-w, Huang J-j, Ye R. 2019. Combination therapy of tripterygium glycosides plus valsartan in diabetic nephropathy treatment: a systematic review and meta-analysis. Chin Herb Med. 11(2):222–230. doi:10.1016/j.chmed.2018.08.011.
   Web of Science ®Google Scholar
• Yu X, Yan D, Lan Q, Fang J, Ding Z, Guan Y, Zhu W, Yan L, Nie H. 2022. Efficacy and safety of jinshuibao capsule in diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials. Comput Math Methods Med. 2022:9671768–9671710. doi:10.1155/2022/9671768.
   PubMed Web of Science ®Google Scholar
• Yung JHM, Giacca A. 2020. Role of c-Jun N-terminal Kinase (JNK) in obesity and type 2 diabetes. Cells. 9(3):706. doi:10.3390/cells9030706.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhang X, Zhang C, Shen Q, Sun G, Sun X. 2019. Notoginsenoside R1 protects db/db mice against diabetic nephropathy via upregulation of Nrf2-Mediated HO-1 expression. Molecules. 24(2):247. doi:10.3390/molecules24020247.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhuang Y, Pan J, Wang H, Li H, Yu Y, Wang D. 2012. Investigation of effects and mechanisms of total flavonoids of Astragalus and Calycosin on human erythroleukemia cells. Oxid Med Cell Longev. 2012:209843–209845. doi:10.1155/2012/209843.
   PubMed Web of Science ®Google Scholar
• Zhang K, Bi Z, Zhang Y, Fang C. 2022. Clinical observation on 30 cases of early diabetes nephropathy treated with Bushen Jianpi Huoxue recipe. Clin J Tradit Chin Med. 34:1540–1543.
   Google Scholar
• Zhao J, Mo C, Meng L, Liang C, Cao X, Shi W. 2019. Efficacy and safety of Buyang Huanwu Decoction for early-stage diabetic nephropathy: a meta-analysis. Chin J Chin Mater Med. 44:1660–1667.
   Google Scholar
• Zhao J, Zhi Y-J, Zhao H, Yu D-D. 2019. Efficacy and safety of Breviscapine injection in treatment of diabetic nephropathy: systematic review and meta-analysis of randomized controlled trials. Chin J Chin Mater Med. 44:833–844.
   Google Scholar
• Zhao T, Sun S, Zhang H, Huang X, Yan M, Dong X, Wen Y, Wang H, Lan HY, Li P. 2016. Therapeutic effects of Tangshen Formula on diabetic nephropathy in rats. PLoS One. 11(1):e0147693. doi:10.1371/journal.pone.0147693.
   PubMed Web of Science ®Google Scholar
• Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, Fang D, Zhang DD. 2011. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes. 60(11):3055–3066. doi:10.2337/db11-0807.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Lee K, Deng Y, Ma Y, Chen Y, Li X, Wei C, Yang S, Wang T, Wong NJ, et al. 2019. Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes. Nat Commun. 10(1):4523. doi:10.1038/s41467-019-12433-w.
   PubMedGoogle Scholar
• Zhou LL, Chen XW, Lu MZ, Wu QY, Yuan Q, Hu CX, Miao JH, Zhang YF, Li HY, Hou FF, et al. 2019. Wnt/β-catenin links oxidative stress to podocyte injury and proteinuria. Kidney Int. 95(4):830–845. doi:10.1016/j.kint.2018.10.032.
   PubMed Web of Science ®Google Scholar
• Zhu JT, Wang WK, Ge F, Sun Y, Li ZH, Xue M. 2022. Danggui Buxue Decoction and its active ingredients improve diabetic nephropathy by inhibiting the activation of NLRP3 inflammasome. Pharmacol Clin Chin Mater Clin Med. 38:31–35.
   Google Scholar
• Zhu Q, Qi X, Wu Y, Wang K. 2016. Clinical study of total glucosides of paeony for the treatment of diabetic kidney disease in patients with diabetes mellitus. Int Urol Nephrol. 48(11):1873–1880. doi:10.1007/s11255-016-1345-5.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Zeng JL, Li J, Chen XM, Miao JX, Jin QY, Chen HY. 2020. Effects of compound centella on oxidative stress and Keap1-Nrf2-ARE pathway expression in diabetic kidney disease rats. Evid Based Complement Alternat Med. 2020:9817932–9817913. doi:10.1155/2020/9817932.
   PubMed Web of Science ®Google Scholar